ViBA

[Does aspirin have a place in primary cardiovascular prevention by the polypill ? Simulation study on a realistic virtual population].

Fall M, Grenet G, Le HH · Therapie · 2023 · Article

10.1016/j.therap.2023.01.011

Verified evidence

Virtual population strategy comparison

258f68e1-80e6-5234-ba14-55c26c466ed0
Risk and probability estimatesTreatment response and effect measures

Prediction source Version of record · PDF page(s) 13

Study 554d4246-4274-50fb-bd4a-99323be9aefb · Prediction record (JSON)

Prediction fields

Endpoint
cardiovascular_prevention_benefit_vs_bleeding_risk__fraction_above_benefit_risk_ratio_threshold · PDF page(s) 13
Family
risk_estimate · PDF page(s) 13
Measured variable
cardiovascular_prevention_benefit_vs_bleeding_risk · PDF page(s) 13
Metric
fraction_above_benefit_risk_ratio_threshold · PDF page(s) 13
Population
human_observations · PDF page(s) 13, 15
Reference type
simulated_against_baseline · PDF page(s) 13
Role
simulated_output · PDF page(s) 13
Scenario
within_model_scenario_comparison · PDF page(s) 13